 Shares of Allogene Therapeutics Inc NASDAQ: ALLO tanked 45 to 13.35 on Friday after the U.S. FDA put a hold on its Cancer drug trial. The sharp decline wiped millions off Allogenes market cap, leaving the California-based firm with a valuation of 1.90 billion. 